



## Preventive Services Statins Zero Copay Exception-REG

### Disclaimer

*Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.*

*Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.*

|                                                      |    |
|------------------------------------------------------|----|
| Preventive Services Statins Zero Copay Exception-REG | 1  |
| Summary                                              | 2  |
| Definitions                                          | 3  |
| Coverage Criteria                                    | 5  |
| References                                           | 5  |
| Appendix A                                           | 7  |
| Clinical Guideline Revision / History Information    | 10 |

## Summary

Statins are a class of medications used to lower high levels of cholesterol and triglycerides in the blood and reduce the risk of cardiovascular disease. They are classified as low-intensity, moderate-intensity, or high-intensity based on their ability to lower low-density lipoprotein (LDL)-cholesterol levels. Statins work by inhibiting an enzyme in the liver that is responsible for producing cholesterol.

Table 1: Statins (hydroxymethylglutaryl-CoA reductase inhibitors) Intensity

| Generic name | High intensity | Moderate intensity                                  | Low intensity |
|--------------|----------------|-----------------------------------------------------|---------------|
| Atorvastatin | 40 to 80 mg    | 10 to 20 mg                                         |               |
| Rosuvastatin | 20 to 40 mg    | 5 to 10 mg                                          |               |
| Simvastatin  |                | 20 to 40 mg                                         | 10 mg         |
| Pravastatin  |                | 40 to 80 mg                                         | 10 to 20 mg   |
| Lovastatin   |                | 40 to 80 mg                                         | 20 mg         |
| Fluvastatin  |                | 80 mg daily (extended-release) or 40 mg twice daily | 20 to 40 mg   |
| Pitavastatin |                | 1 to 4 mg                                           |               |

### Statin Use for the Primary Prevention of Cardiovascular Disease in Adults:

The United States Preventive Services Task Force (USPSTF) provides recommendations based on population groups and cardiovascular risk:

1. For adults aged 40 to 75 years with one (1) or more cardiovascular risk factors and an estimated 10-year cardiovascular disease (CVD) risk of 10% or greater, the USPSTF recommends initiating a statin (Grade: B). (See [Definitions](#) below for a complete list of USPSTF defined cardiovascular risk factors)
2. For adults aged 40 to 75 years with one (1) or more cardiovascular risk factors and an estimated 10-year CVD risk of 7.5% to less than 10%, the USPSTF recommends selectively offering statins for primary prevention of CVD (Grade: C).
3. The current evidence is insufficient to assess the benefits and harms of initiating a statin for the primary prevention of CVD events and mortality in adults 76 years or older.

These recommendations apply to adults 40 years or older without established CVD or signs of CVD. They do not apply to adults with a LDL cholesterol level greater than 190 mg/dL (4.92 mmol/L) or known familial hypercholesterolemia.

- I. Initiate a moderate-intensity statin for those with a risk factor and a 10-year CVD risk of 10% or greater, after patient agreement.

- II. For those with a risk factor and a 10-year CVD risk of 7.5% to less than 10%, selectively offer a statin considering patient values and preferences.
- III. To implement these recommendations, clinicians should consider the patient's age, presence of cardiovascular risk factors, and estimated CVD risk.
  - A. CVD is the leading cause of mortality in the US, making these recommendations crucial.
  - B. Age is a significant risk factor for CVD.

Additional resources can be found on the [Million Hearts initiative](#) and [Centers for Disease Control and Prevention](#) websites. For the full recommendation statement, visit the USPSTF or the Journal of the American Medical Association (JAMA) website.

#### **Preventive Services Statins Zero Copay Exception**

*The Plan is committed to facilitating a \$0 member cost share for a brand low/moderate intensity statin or brand/generic high intensity statin when it's determined to be medically necessary for primary prevention of cardiovascular disease in adults aged 40 to 75 years. Please note that this coverage does not extend to individuals with a low-density lipoprotein cholesterol (LDL-C) level greater than 190 mg/dL (4.92 mmol/L) or known familial hypercholesterolemia, as the USPSTF recommendation does not apply to these cases. It is also important to note that the initiation or titration to 80 mg of simvastatin is not recommended by the FDA due to the increased risk of myopathy, including rhabdomyolysis.*

#### **Definitions**

"ASCVD" refers to atherosclerotic cardiovascular disease.

"ASCVD Risk Estimator" is a peer-reviewed online calculator which uses the Pooled Cohort Equations to estimate the 10-year primary risk of ASCVD (atherosclerotic cardiovascular disease) among patients without pre-existing cardiovascular disease who are between 40 and 79 years of age.

"Cardiovascular Event" is a health incident that affects the heart or blood vessels, such as a heart attack or stroke.

"Cardiovascular Risk Factors" are conditions or habits that increase the chances of developing cardiovascular disease. They encompass a wide range of factors, such as:

1. Age: Men aged 45 years or older and women aged 55 years or older are at higher risk.
2. Diabetes: A chronic condition that affects the body's ability to use sugar for energy and can cause damage to the blood vessels.
3. Dyslipidemia: An abnormal amount of lipids (like cholesterol and/or fat) in the blood.
4. Excessive Alcohol Use: Drinking too much alcohol can raise blood pressure and contribute to heart disease.
5. Family history of early heart disease: Heart disease in a father or brother before age 55, or in a mother or sister before age 65, can indicate a genetic predisposition to cardiovascular conditions.

6. Hypertension: High blood pressure, which can cause strain on the heart and contribute to atherosclerosis (hardening of the arteries).
7. Obesity: A body mass index (BMI) of 30 or higher, which puts strain on the heart.
8. Poor Diet: Diets high in saturated fats, trans fats, sodium, and cholesterol can raise blood cholesterol levels and contribute to heart disease.
9. Sedentary Lifestyle: Lack of physical activity can contribute to the development of heart disease.
10. Smoking: Tobacco use contributes to the buildup of plaque in the blood vessels and can lead to heart disease.

"Cholesterol" is a type of fat molecule that is essential for building cell membranes and producing hormones, but high levels of cholesterol in the blood can increase the risk of cardiovascular disease.

"Familial Hypercholesterolemia" is a genetic disorder characterized by high cholesterol levels, specifically high levels of LDL-C, in the blood.

"High-intensity statin" is a statin with LDL-lowering capacity of 50% or greater.

"Hyperlipidemia" is a condition characterized by high levels of lipids (fats) in the blood, including cholesterol and triglycerides.

"Low-density lipoprotein cholesterol (LDL-C)" is a type of cholesterol that is often referred to as "bad" cholesterol because high levels of LDL-C can increase the risk of cardiovascular disease. Statins and other medications are often used to lower LDL-C levels.

"Moderate-Intensity statin" is a statin with LDL-lowering capacity of 30-49%.

"Preventive Services Statins Zero Copay Exception" is a provision in the health plan where the member doesn't have to pay any out-of-pocket costs (copay) for statins when used for the primary prevention of cardiovascular disease.

"Primary prevention" is used to reduce the risk of future atherosclerotic cardiovascular disease (ASCVD) events.

"Secondary prevention" is used to treat existing ASCVD and to prevent it from getting worse.

"Statins" are a class of medications used to lower cholesterol levels and reduce the risk of cardiovascular disease by inhibiting an enzyme involved in cholesterol synthesis.

"Triglycerides" are a type of fat molecule that is used for energy storage in the body, but high levels of triglycerides in the blood can increase the risk of cardiovascular disease.

“U.S. Preventive Services Task Force (USPSTF) recommendations” are based on a rigorous review of existing peer-reviewed evidence and are intended to help primary care clinicians and patients decide together whether a preventive service is right for a patient's needs.

### Coverage Criteria

The requested product will be covered at \$0 member cost share when the following criteria are met:

1. The member is aged 40 to 75 years, and the statin is needed for primary prevention of cardiovascular disease; *AND*
2. The member has an estimated 10-year risk of a cardiovascular event of 10 percent or greater; *AND*
3. The member has ONE (1) or more cardiovascular risk factors, which may include but are not limited to the following:
  - a. Age (men aged 45 years or older; women aged 55 years or older); *and/or*
  - b. Diabetes; *and/or*
  - c. Dyslipidemia; *and/or*
  - d. Family history of early heart disease (heart disease in father or brother before age 55; heart disease in mother or sister before age 65); *and/or*
  - e. Hypertension; *and/or*
  - f. Obesity (Body Mass Index (BMI) of 30 or higher); *and/or*
  - g. Smoking; *AND*
4. The member meets ALL of the following criteria:
  - a. No evidence of an low-density lipoprotein cholesterol (LDL-C) level greater than 190 mg/dL (4.92 mmol/L); *and*
  - b. No evidence of familial hypercholesterolemia; *and*
  - c. No evidence of existing atherosclerotic cardiovascular disease (ASCVD).

If the above prior authorization criteria are met, the requested product will be authorized for up to 36 months at a \$0 member cost share as preventive services.

### References

1. American College of Endocrinology Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease- 2017. Endocrine Practice - 2017 April; 23(Supplement 2): S97-S115.
2. American Diabetes Association Professional Practice Committee for Diabetes\*. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 1;49(Suppl 1):S216-S245. doi: 10.2337/dc26-S010. PMID: 41358899; PMCID: PMC12690187.
3. Arnett DK et al: 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 74(10):e177-232, 2019
4. Asians. Int J Endocrinol Metab. 2017 Apr; 15(2): e43319. Published online 2017 Apr 22. doi: 10.5812/ijem.43319.

5. Barayev O, Hawley CE, Wellman H, et al. Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease. *JAMA Netw Open*. 2023 Dec 1;6(12):e2346373. doi: 10.1001/jamanetworkopen.2023.46373.
6. Chou R, Cantor A, Dana T, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA*. Published August 23, 2022. doi:10.1001/jama.2022.12138
7. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines *J Am Coll Cardiol*. 2013 Nov; S0735-1097(13)06029-4.
8. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N Engl J Med*. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30. Erratum in: *N Engl J Med*. 2010 Apr 15;362(15):1450.
9. Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019; 139:e1082-e1143
10. Hla D, Blumenthal RS, Martin SS, et al. Assessing Severity of Statin Side Effects: Fact Versus Fiction. *American College of Cardiology*. Apr 09, 2018.
11. Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. *Am J Kidney Dis*. 2010 Jan;55(1):42-9. doi: 10.1053/j.ajkd.2009.09.020. Epub 2009 Nov 22.
12. Kostapanos MS, Elisaf MS. JUPITER and satellites: clinical implication of the JUPITER study and its secondary analyses. *World J Cardiol*. 2011 Jul 26; 3(7):207-14. doi:10.4330/wjc.v3.i7.207.
13. Kostapanos MS, Liberopoulos EN, Elisaf MS. Statin pleiotropy against renal injury. *J Cardiometab Syndr*. 2009;4:E4–E9. doi: 10.1111/j.1559-4572.2008.00052.x.
14. Mach F et al: 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 41(1):111-88, 2020
15. März W, Genser B, Drechsler C, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. *Clin J Am Soc Nephrol*. 2011 Jun;6(6):1316-25. doi: 10.2215/CJN.09121010. Epub 2011 Apr 14.
16. Nakamura H, Mizuno K, Ohashi Y, et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. *Atherosclerosis*. 2009 Oct;206(2):512-7. doi: 10.1016/j.atherosclerosis.2009.03.031. Epub 2009 Apr 5.
17. O'Malley PG et al: Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2020 updated U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. *Ann Intern Med*. 173(10):822-9, 2020
18. Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. *J Am Coll Cardiol*. 2010 Mar 23;55(12):1266-1273. doi: 10.1016/j.jacc.2010.01.020. Epub 2010 Mar 4.
19. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013 Nov 12.
20. US Preventive Services Task Force. Collaboration and shared decision-making between patients and clinicians in preventive health care decisions and US Preventive Services Task Force recommendations. *JAMA*. 2022;327(12):1171-1176. doi:10.1001/jama.2022.3267

21. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;316(19):1997-2007. doi:10.1001/jama.2016.15450
22. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: preventive medication. August 23, 2022. <https://uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication>. (Accessed September 8, 2025).
23. Virani SS, Newby LK, Arnold SV, et al; Peer Review Committee Members. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9-e119. doi: 10.1161/CIR.0000000000001168. Epub 2023 Jul 20. Erratum in: Circulation. 2023 Sep 26;148(13):e148. doi: 10.1161/CIR.0000000000001183. Erratum in: Circulation. 2023 Dec 5;148(23):e186. doi: 10.1161/CIR.0000000000001195. PMID: 37471501.
24. Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022 May;28(5):e1-e167. doi: 10.1016/j.cardfail.2022.02.010. Epub 2022 Apr 1. PMID: 35378257.

## Appendix A

### Reduction in Risk of Cardiovascular Events

#### General Recommendation

1. The American Heart Association (AHA)/American College of Cardiology (ACC) cholesterol management guideline recommends statins as first-line therapy for reducing the risk of atherosclerotic cardiovascular disease (ASCVD) in adults.
2. Evidence shows that statins substantially reduce low-density lipoprotein (LDL)-cholesterol concentrations and associated ASCVD risk.
3. The maximum tolerated statin intensity should be used to achieve optimum ASCVD benefits.
4. The ACC/AHA guideline recommends statin therapy for primary prevention of CVD in the following populations:
  - a. Those 40-75 years with an LDL-cholesterol  $\geq 70$  -  $< 190$  mg/dl without Diabetes Mellitus and 10-year ASCVD risk of 5-  $< 7.5\%$ : consider a risk discussion "if risk enhancers present then risk discussion regarding moderate-intensity statin therapy." (Class IIb)
  - b. Those 40-75 years with an LDL-cholesterol  $\geq 70$  -  $< 190$  mg/dl without Diabetes Mellitus and 10-year ASCVD risk of  $\geq 7.5\%$  -  $< 20\%$ : consider a risk discussion: "If risk estimate + risk enhancers favor statin, initiate moderate-intensity statin to reduce LCL-C by 30-49%" (Class I)
  - c. Those 40-75 years with an LDL-cholesterol  $\geq 70$  -  $< 190$  mg/dl without Diabetes Mellitus and 10-year ASCVD risk of  $\geq 20\%$ : consider a risk discussion: "Initiate statin to reduce LDL-C by  $\geq 50\%$ ." (Class I)
  - d. In those with LDL-C  $\geq 190$  mg/dl ( $\geq 4.9$  mmol/L): "No risk assessment; High intensity statin." (Class I)
  - e. In those with Diabetes mellitus and age 40-75 years: "Moderate intensity statin." (Class I)
  - f. In those with Diabetes Mellitus and age 40-75 years: "Risk assessment to consider high intensity statin." (Class IIa)

- g. In those 20-39 years: "To encourage lifestyle to reduce ASCV risk; consider statin if family history [of] premature ASCVD and LDL-C  $\geq 160$  mg/dl ( $\geq 4.1$  mmol/L)."
- 5. ACA/AHA guidelines define "risk enhancers" as the following:
  - a. Family history of premature ASCVD
  - b. Persistent elevated LDL-C  $\geq 160$  mg/dl ( $\geq 4.1$  mmol/L)
  - c. Chronic kidney disease
  - d. Metabolic syndrome
  - e. Conditions specific to women (e.g., preeclampsia, premature menopause)
  - f. Inflammatory disease (especially rheumatoid arthritis, psoriasis, HIV)
  - g. Ethnicity (e.g., South Asian ancestry)
  - h. Lipid biomarkers:
    - i. Persistently elevated triglycerides ( $\geq 175$  mg/dl, ( $\geq 2.0$  mmol/L))
  - i. In selected individuals if measured:
    - i. High-sensitivity C-reactive protein (hs-CRP)  $\leq 2.0$  mg/L
    - ii. Lp(a) levels  $> 50$  mg/dl or  $> 125$  nmol/L
    - iii. apoB  $\geq 130$  mg/dl
    - iv. Ankle-brachial index (ABI)  $< 0.9$

#### Primary Prevention with Statins

1. Statins are used with diet and lifestyle modifications in those without clinical evidence of coronary heart disease but with an increased risk of cardiovascular disease.
2. High-risk individuals are identified by age, high-sensitivity C-reactive protein concentrations, and additional cardiovascular disease risk factors (see [Definitions](#) above).
3. A shared decision-making approach between the member and clinician is recommended when considering statin therapy for primary prevention.
4. Statin therapy in high-risk individuals has been shown to reduce the risk of major cardiovascular events.

#### Reducing Progression of Coronary Atherosclerosis

1. Statins are used to slow the progression of atherosclerosis as part of a treatment strategy to lower total and LDL-cholesterol concentrations to target levels.
2. Studies have shown that statins slows the progression of atherosclerosis in those with elevated LDL-cholesterol concentrations and subclinical atherosclerosis.

#### Secondary Prevention with Statins

1. Statins are used for secondary prevention in those with established ASCVD.
2. The 2018 AHA/ACC cholesterol management guideline emphasizes lifestyle modification as the foundation of ASCVD risk reduction.
3. Those with clinical ASCVD should also be treated with a statin in conjunction with lifestyle modification to reduce LDL-cholesterol concentrations.
4. AHA/ACC recommends the use of high-intensity statin therapy.



5. This criteria does not apply to those being treated with statins for secondary prevention.

#### Intensity of Statin Therapy

1. The appropriate intensity of a statin should be used to reduce the risk of ASCVD and should be individualized.
2. Statins of different doses are grouped into intensity level (low, moderate or high-intensity) based on LDL-cholesterol reduction percentage from baseline.

#### Combination Antilipemic Therapy

1. Combination therapy with a non-statin drug may be useful in high-risk individuals who require further reduction in LDL-cholesterol concentrations.
2. If combination therapy is necessary, selection of the non-statin drug should be based on the risk and benefit profile and patient preferences.

#### Those with Chronic Kidney Disease

1. Studies on statin benefits in those with chronic kidney disease showed that therapy did not substantially reduce the primary composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke compared with placebo.
2. Chronic kidney disease (CKD) is considered a "risk enhancer" per the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.
3. A secondary analysis of the JUPITER (Justification for the Use of statins in Prevention-an Intervention Trial Evaluating Rosuvastatin), which recruited n=3,267 participants with reduced kidney function, identified that those with moderate CKD experienced a 45% reduction in composite primary outcome of myocardial infarction, stroke, hospital stay for unstable angina, arterial revascularization or confirmed cardiovascular death (HR 0.55, 95% CI: 0.38-0.82, p=0.002). They also realized a 44% reduction in all-cause mortality (HR 0.56, 95% CI:0.37-0.85, p=0.005). These results were similar for those with preserved kidney function in the JUPITER study.
4. In a large cohort study of 14,828 older adult ( $\geq 65$  years of age) veterans with stage 3 or 4 CKD, it was found that those who initiated a statin had a lower risk of all-cause major adverse cardiovascular events (HR 0.91, 95% CI, 0.85-0.97), compared to those who did not initiate a statin.
5. In a post-hoc analysis of the MEGA randomized controlled trial, it was found that the risk of CVD events was higher in those with moderate CKD compared to those with normal kidney function or mild CKD (35-49% higher risk). In those who initiated pravastatin with moderate CKD, the risk of coronary heart disease (CHD) was reduced by 48%, the risk of stroke was reduced by 73%, the risk of CVD was reduced by 55% and the risk of total mortality was reduced by 51%.
6. In a post-hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention study, lovastatin was shown to significantly reduce the risk of fatal and non-fatal CVD events in those with moderate CKD (RR 0.31, 95% CI, 0.13-0.72, p=0.01) and no history of ASCVD.

7. In a multicenter international randomized controlled study of 2776 participants with CKD on hemodialysis (ages 50-80), rosuvastatin significantly reduced LDL-C, but did not significantly reduce the risk of CVD events (composite of death from CVD cause, nonfatal myocardial infarction, or nonfatal stroke) compared to placebo. Conversely, in a post-hoc analysis of the 4D (Die Deutsche Diabetes Dialyse) study, atorvastatin significantly reduced the risk of fatal and non-fatal cardiac events in those with type 2 diabetes undergoing hemodialysis (HR 0.69, 95% CI, 0.48-1.00) with the highest quartile of LDL-C ( $\geq 145$  mg/dl).

#### Clinical Guideline Revision / History Information

Original Date: 7/31/2023

Reviewed/Revised: 12/19/2024, 01/01/2026, 01/04/2027